| 原发性肝癌新辅助治疗进展 |
| |
| 引用本文： | 肖永胜,郭磊,周俭. 原发性肝癌新辅助治疗进展[J]. 腹部外科, 2021, 34(1): 1-3,9 |
| |
| 作者姓名： | 肖永胜 郭磊 周俭 |
| |
| 作者单位： | 复旦大学附属中山医院肝外科复旦大学肝癌研究所,上海200032;复旦大学附属中山医院肝外科复旦大学肝癌研究所,上海200032;复旦大学附属中山医院肝外科复旦大学肝癌研究所,上海200032 |
| |
| 基金项目： | 国家重点研发计划(2019YFC1315800,2019YFC1315802)。 |
| |
| 摘 要： | 原发性肝癌作为一个全球性疾病,其发病率和死亡率均位居恶性肿瘤前列,但是其手术切除率低、术后复发率高,严重限制了病人生存率的提升.新辅助治疗能够通过术前干预降低术后肿瘤的复发率.此文将对肝癌新辅助治疗的进展以及亟待解决的问题进行总结,希望可以为肝癌诊治带来新的启发.
|
| 关 键 词： | 原发性肝癌 新辅助治疗 |
Recent advances of neoadjuvant therapy for primary liver cancer |
| |
| Xiao Yongsheng,Guo Lei,Zhou Jian. Recent advances of neoadjuvant therapy for primary liver cancer[J]. Journal of Abdominal Surgery, 2021, 34(1): 1-3,9 |
| |
| Authors: | Xiao Yongsheng Guo Lei Zhou Jian |
| |
| Affiliation: | (Department of Liver Surgery&Transplantation,Liver Cancer Institute,Zhongshan Hospital,Fudan University,Shanghai 200032,China) |
| |
| Abstract: | As a global disease,primary liver cancer ranks high among malignant tumors in morbidity and mortality.However,its low surgical resection rate and high postoperative recurrence rate have greatly limited the improvement of patient survival.Neoadjuvant therapy reduces the postoperative tumor recurrence rate by preoperative treatment.Neoadjuvant therapy for primary liver cancer and outstanding problems were summarized for guiding its diagnosis and treatment. |
| |
| Keywords: | Primary liver cancer Neoadjuvant therapy |
| 本文献已被 CNKI 维普 万方数据 等数据库收录！ |
|
